Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SILVA: BEC2 and BCG in limited-stage small cell lung cancer
NCT00003279Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 1998
- Primary completion
- Jan 2000
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of blinatumomab in small cell lung cancer (SCLC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall Survival. Started Mar 1998; status: completed.
02
Drugs
blinatumomab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00003279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003279.